High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
By J. Haroche, F. Charlotte, L. Arnaud, A. von Deimling, Z. Hélias-Rodzewicz, B. Hervier, F. Cohen-Aubart, D. Launay, Annette Lesot, K. Mokhtari and 13 more. Blood, 2012
660 citations recorded by the source corpus.
Subfields: Pathology and Forensic Medicine, Physiology, Surgery
View Paper: https://www.semanticscholar.org/paper/04d9a64f8c8e02c32bc51f85f8f431e167f67d82
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pathology and Forensic Medicine
Citations in the corpus
- Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. (2016, methodology): “V600E mutations.(6) Detection of BRAF mutants in ECD and LCH requires methods of higher sensitivity than for other neoplasia due to allele fraction ,10% in some cases (grade C2).”
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (2015, neutral): “(%) 8 (42) 0 1 (4) 1 (12) 5 (36) 1 (14)”
- Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years (2012, positive): “[53], reported somatic mutations of the BRAF oncogene in about half of the LCH patients in their series, and this finding was recently confirmed by other teams [54,55].”